MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 01-29-2026
Pro-Dex Balance Sheet 2011-2026 | PDEX
Annual Balance Sheet Pro-Dex
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
15 M | -1.45 M | 9.86 M | 1.2 M | -1.29 M | -3.14 M | -3.19 M | -5.15 M | -4.12 M | -2.22 M | -603 K | -3.17 M | -1.66 M | -3.34 M | -3.56 M |
Long Term Debt |
15.4 M | 1.18 M | 12.8 M | 2.05 M | 2.43 M | 3.28 M | 3.93 M | - | 61 K | 46 K | 70 K | - | - | - | 774 K |
Total Non Current Liabilities |
9.93 M | 8.72 M | 10.6 M | 12.3 M | 14 M | 6.84 M | 4.24 M | 103 K | 61 K | 193 K | 344 K | 365 K | 344 K | 393 K | 1.22 M |
Total Current Liabilities |
14.6 M | 12.9 M | 9.68 M | 11.4 M | 6.27 M | 5.23 M | 4.27 M | 2.54 M | 2.58 M | 2.08 M | 3.69 M | 2.13 M | 2.31 M | 2.88 M | - |
Total Liabilities |
24.6 M | 21.6 M | 20.2 M | 23.6 M | 20.2 M | 12.1 M | 8.51 M | 2.64 M | 2.64 M | 2.27 M | 4.04 M | 2.49 M | 2.66 M | 3.27 M | 5.24 M |
Deferred Revenue |
202 K | 14 K | - | 1.01 M | 150 K | 200 K | 215 K | 31 K | 19 K | 212 K | 594 K | 232 K | 141 K | - | - |
Retained Earnings |
35.9 M | 27 M | 24.8 M | 21.7 M | 15.3 M | 9.91 M | 1.74 M | -2.41 M | -4.03 M | -9.11 M | -9.93 M | -9.57 M | -9.08 M | -7.3 M | -6.42 M |
Total Assets |
61.2 M | 52.5 M | 51.8 M | 51.9 M | 43.3 M | 39.1 M | 25.5 M | 19.9 M | 16.4 M | 11.1 M | 12.5 M | 11.7 M | 10.6 M | 12.8 M | 15.6 M |
Cash and Cash Equivalents |
419 K | 2.63 M | 2.94 M | 849 K | 3.72 M | 6.42 M | 7.74 M | 5.19 M | 4.2 M | 2.29 M | 697 K | 3.19 M | 1.68 M | 4.11 M | 4.69 M |
Book Value |
36.6 M | 30.9 M | 31.6 M | 28.2 M | 23.1 M | 27 M | 17 M | 17.3 M | 13.7 M | 8.88 M | 8.48 M | 9.22 M | 7.94 M | 9.55 M | 10.3 M |
Total Shareholders Equity |
36.6 M | 30.9 M | 31.6 M | 25.4 M | 21.1 M | 19.1 M | 17 M | 17.3 M | 13.7 M | 8.88 M | 8.48 M | 9.22 M | 7.94 M | 9.55 M | - |
All numbers in USD currency
Quarterly Balance Sheet Pro-Dex
| 2025-Q4 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
419 K | 685 K | 813 K | 939 K | 1.06 M | 1.18 M | 1.3 M | 1.42 M | 1.53 M | 1.64 M | 1.74 M | 1.85 M | 1.95 M | 2.05 M | 10.6 M | 10.9 M | 11.2 M | 12.8 M | 11.5 M | 8.38 M | 3.11 M | 3.98 M | 3.28 M | 3.61 M | 3.78 M | 4.6 M | 3.93 M | 4.25 M | 4.45 M | 6 K | 6 K | - | - | 61 K | - | - | - | 46 K | - | - | - | - | - | - | - | - | - | - | - | - | 403 K | 389 K | 391 K | 393 K | 393 K | 1.04 M | 1.13 M | 1.22 M | 1.22 M |
Total Non Current Liabilities |
8.42 M | 9.93 M | 10.7 M | 11.4 M | 12.1 M | 8.72 M | 9.19 M | 9.65 M | 10.1 M | 10.6 M | 11 M | 11.4 M | 11.9 M | 12.3 M | 13.9 M | 14.1 M | 14.3 M | 14.4 M | 14.4 M | 11.6 M | 6.3 M | 6.84 M | 6.84 M | 6.9 M | 6.98 M | 4.24 M | 4.24 M | 4.37 M | 4.56 M | 226 K | 103 K | 98 K | 99 K | 61 K | 61 K | 114 K | 150 K | 114 K | 114 K | 274 K | 296 K | 344 K | 344 K | 368 K | 351 K | 365 K | 365 K | 325 K | 335 K | 344 K | 344 K | - | - | 393 K | - | - | - | - | - |
Total Liabilities |
20.6 M | 24.6 M | 29 M | 28.6 M | 23.4 M | 21.6 M | 19.6 M | 19.6 M | 18.4 M | 20.2 M | 21.1 M | 23.1 M | 23.5 M | 23.7 M | 21.6 M | 20.1 M | 20.5 M | 20.2 M | 20.2 M | 16.5 M | 10.7 M | 12.1 M | 12.1 M | 10.9 M | 10.5 M | 3.3 M | 3.3 M | 7.04 M | 7.47 M | 2.64 M | 2.64 M | 2.07 M | 1.89 M | 2.64 M | 2.64 M | 2.83 M | 2.8 M | 2.27 M | 2.27 M | 3.4 M | 3.91 M | 4.04 M | 4.04 M | 3.06 M | 2.48 M | 2.49 M | 2.49 M | 2.34 M | 2.23 M | 2.66 M | 2.66 M | 2.02 M | 3.01 M | 3.27 M | 3.27 M | 4.8 M | 4.53 M | 5.24 M | 5.24 M |
Deferred Revenue |
163 K | 202 K | - | - | - | 14 K | 35 K | - | - | - | 57 K | 851 K | 851 K | 1.01 M | 896 K | 584 K | 293 K | 150 K | 150 K | 200 K | 200 K | 200 K | 200 K | 360 K | 240 K | 215 K | 215 K | 30 K | 70 K | 31 K | 31 K | - | 18 K | 19 K | 19 K | 452 K | 319 K | 212 K | 212 K | 282 K | 620 K | 594 K | 594 K | 501 K | 247 K | 232 K | 232 K | 247 K | 212 K | 141 K | 141 K | - | - | 20 K | - | - | - | - | - |
Retained Earnings |
41.6 M | 35.9 M | 34.7 M | 31.5 M | 29.4 M | 27 M | 25.4 M | 24.7 M | 24.2 M | 24.8 M | 19.3 M | 17.9 M | 17.1 M | 16 M | 14.6 M | 14.1 M | 13.2 M | 12.1 M | 12.1 M | 9.5 M | 9.16 M | 7.9 M | 7.9 M | 4.14 M | 2.89 M | 1.74 M | 1.74 M | 122 K | -1.06 M | -2.41 M | -2.41 M | -3.05 M | -3.4 M | -4.03 M | -4.03 M | -5.63 M | -8.82 M | -9.11 M | -9.11 M | -9.67 M | -10.1 M | -9.93 M | -9.93 M | -9.93 M | -9.74 M | -9.57 M | -9.57 M | -9.21 M | -8.87 M | -9.08 M | -9.08 M | -7.66 M | -7.31 M | -7.3 M | -7.3 M | -6.27 M | -5.97 M | -6.42 M | -6.42 M |
Total Assets |
62.3 M | 61.2 M | 64.3 M | 60.4 M | 54.3 M | 52.5 M | 50.5 M | 51.4 M | 49.6 M | 51.8 M | 47 M | 47.6 M | 48 M | 47.3 M | 43.9 M | 42.1 M | 41.9 M | 40.3 M | 40.3 M | 38.4 M | 30.8 M | 31.1 M | 31.1 M | 28.7 M | 28 M | 25.5 M | 25.5 M | 24 M | 25.2 M | 19.9 M | 19.9 M | 18.8 M | 18.2 M | 16.4 M | 16.4 M | 15 M | 11.9 M | 11.1 M | 11.1 M | 12.2 M | 12.3 M | 12.5 M | 12.5 M | 11.9 M | 11.5 M | 11.7 M | 11.7 M | 10.4 M | 10.5 M | 10.6 M | 10.6 M | 11.3 M | 12.6 M | 12.8 M | 12.8 M | 15.3 M | 15.3 M | 15.6 M | 15.6 M |
Cash and Cash Equivalents |
5.27 M | 33 K | 33 K | 66 K | 3.08 M | 45 K | 3.22 M | 1.29 M | 1.9 M | 2.94 M | 2.09 M | 382 K | 2.8 M | 849 K | 4.76 M | 5.25 M | 5.18 M | 3.72 M | 3.72 M | 5.52 M | 5.2 M | 5.52 M | 5.2 M | 6.18 M | 6.5 M | 6.18 M | 6.5 M | 8.87 M | 8.32 M | 8.87 M | 8.32 M | 5.26 M | 5.86 M | 5.26 M | 5.86 M | 2.18 M | 2.17 M | 2.18 M | 2.17 M | 1.05 M | 493 K | 1.05 M | 493 K | 1.97 M | 3.61 M | 1.97 M | 3.61 M | 1.55 M | 1.83 M | 1.55 M | 1.83 M | 2.55 M | 3.12 M | 2.55 M | 3.12 M | 4.27 M | 4.91 M | 4.27 M | 4.91 M |
Book Value |
41.6 M | 36.6 M | 35.3 M | 31.8 M | 30.9 M | 30.9 M | 30.9 M | 31.8 M | 31.2 M | 31.6 M | 25.8 M | 24.5 M | 24.4 M | 23.7 M | 22.3 M | 22 M | 21.4 M | 20.1 M | 20.1 M | 21.8 M | 20.1 M | 19.1 M | 19.1 M | 17.9 M | 17.4 M | 22.2 M | 22.2 M | 17 M | 17.7 M | 17.3 M | 17.3 M | 16.7 M | 16.3 M | 13.7 M | 13.7 M | 12.2 M | 9.13 M | 8.88 M | 8.88 M | 8.77 M | 8.36 M | 8.48 M | 8.48 M | 8.88 M | 9.06 M | 9.22 M | 9.22 M | 8.05 M | 8.22 M | 7.94 M | 7.94 M | 9.3 M | 9.56 M | 9.55 M | 9.55 M | 10.5 M | 10.8 M | 10.3 M | 10.3 M |
Total Shareholders Equity |
41.6 M | 36.6 M | 35.3 M | 31.8 M | 30.9 M | 30.9 M | 30.9 M | 31.8 M | 31.2 M | 31.6 M | 29.9 M | 28.2 M | 26.3 M | 23.7 M | 22.3 M | 22 M | 21.4 M | 20.1 M | 20.1 M | 21.8 M | 21.8 M | 21.8 M | 20.1 M | 17.9 M | 17.9 M | 17.9 M | 17.4 M | 17 M | 17.7 M | 17 M | 17.7 M | 16.7 M | 16.3 M | 16.7 M | 16.3 M | 12.2 M | 9.13 M | 8.88 M | 8.88 M | 8.77 M | 8.36 M | 8.48 M | 8.48 M | 8.88 M | 9.06 M | 9.22 M | 9.22 M | 8.05 M | 8.22 M | 7.94 M | 7.94 M | 9.3 M | 9.56 M | 9.55 M | 9.55 M | 10.5 M | 10.8 M | 10.3 M | 10.3 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Pro-Dex, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Medical instruments
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M |  USA |
 |
Becton, Dickinson and Company
BDX
|
$ 154.51 | -1.17 % | $ 44.4 B | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Repligen Corporation
RGEN
|
$ 117.78 | -0.46 % | $ 6.56 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
$ 9.4 | -11.74 % | $ 22.8 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 56.83 | 1.05 % | $ 2.86 B | USA |
 |
ICU Medical
ICUI
|
$ 123.31 | -1.53 % | $ 3.04 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 452.07 | -2.67 % | $ 161 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 5.2 | 2.16 % | $ 231 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
AngioDynamics
ANGO
|
$ 10.31 | -13.65 % | $ 421 M | USA |
 |
Repro Med Systems
KRMD
|
$ 4.32 | 1.17 % | $ 200 M | USA |
 |
AtriCure
ATRC
|
$ 29.07 | 2.68 % | $ 1.39 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 23.0 | -0.13 % | $ 1.55 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 9.29 | -0.11 % | $ 192 M | USA |
 |
Masimo Corporation
MASI
|
$ 178.59 | 0.33 % | $ 9.52 B | USA |
 |
iRhythm Technologies
IRTC
|
$ 116.8 | -1.2 % | $ 3.74 B | USA |
 |
Merit Medical Systems
MMSI
|
$ 67.7 | -0.78 % | $ 4 B | USA |
 |
BioLife Solutions
BLFS
|
$ 19.51 | 1.14 % | $ 899 M | USA |
 |
electroCore
ECOR
|
$ 6.8 | 3.03 % | $ 57.7 K | USA |
 |
STERIS plc
STE
|
$ 218.71 | -0.56 % | $ 21.6 B | USA |
 |
Teleflex Incorporated
TFX
|
$ 117.81 | -0.52 % | $ 5.26 B | USA |
 |
Utah Medical Products
UTMD
|
$ 63.12 | 0.4 % | $ 205 M | USA |
 |
OraSure Technologies
OSUR
|
$ 3.08 | 0.98 % | $ 226 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 254.8 | 0.82 % | $ 18.4 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 11.63 | -0.26 % | $ 2.32 B | USA |
 |
Glaukos Corporation
GKOS
|
$ 112.77 | 0.12 % | $ 5.46 B | USA |
 |
ResMed
RMD
|
$ 224.09 | 0.56 % | $ 32.7 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
Baxter International
BAX
|
$ 16.68 | -0.6 % | $ 8.56 B | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 20.21 | 4.55 % | $ 1 B | USA |
 |
Stereotaxis
STXS
|
$ 1.87 | 1.08 % | $ 170 M | USA |
 |
The Cooper Companies
COO
|
$ 70.17 | -1.76 % | $ 14 B | USA |
 |
LeMaitre Vascular
LMAT
|
$ 108.49 | -0.24 % | $ 2.46 B | USA |
 |
Microbot Medical
MBOT
|
$ 2.4 | 1.27 % | $ 110 M |  Israel |
 |
Nephros
NEPH
|
$ 2.87 | -2.21 % | $ 29.8 M | USA |
 |
Envista Holdings Corporation
NVST
|
$ 25.81 | -0.35 % | $ 4.34 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.28 | -4.86 % | $ 23 M | USA |
 |
Alcon
ALC
|
$ 74.56 | -1.26 % | $ 40.4 B |  Schweiz |
 |
Retractable Technologies
RVP
|
$ 0.69 | 2.99 % | $ 20.7 M | USA |